Entity

Time filter

Source Type

San Francisco, CA, United States

Patent
Invitae | Date: 2013-12-06

Methods for multiplex ligation-dependent probe amplification include (a) providing a sample tissue to query different target nucleic acids, (b) providing different probe sets for each of the target nucleic acids, each probe set including a first locus specific probe having a first adapter sequence and a first target specific portion and a second locus specific probe having a second adapter sequence, and a second target specific portion adjacent to the first target specific portion, (c) hybridizing the probe sets to the target sequences to form hybridization complexes, (d) ligating the hybridization complexes to form ligated probes, (e) amplifying the ligated probes to form amplicons, the amplifying step being carried out with a first universal primer including a region complementary to the first adapter sequence and a second universal primer including a region complementary to the second adapter sequence, and (f) detecting the amplicons in a detection system by sequencing each of the amplicons.


SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE: NVTA), a genetic information company, today announced that it has more than doubled the size of its genetic testing platform to include more than 600 genes and will release the new content between now and the end of the year. Invitae is immediately expanding its menu with dozens of new test panels for hereditary cancer, cardiovascular, neuromuscular, pediatric, and other rare disorders. With this expanded test menu, Invitae will be able to provide clinicians, patients, and payers with high-quality genetic information for a greatly expanded number of genes and disorders, all at the same price and with rapid turnaround times. “We successfully increased our capacity to test for more than 600 genes, an increase from our initial plan of more than 500 genes, without increasing our prices. We are proud to now offer many more comprehensive and affordable cancer and cardiology genetic test panels, as well as expanded neuromuscular, pediatric, and rare disease test panels, to help clinicians and their patients,” said Randy Scott, chairman and CEO of Invitae. “Importantly, we’re delivering on our promise of lowering the cost of genetic testing to ensure cost is not a barrier for patients and to make a positive impact on the otherwise skyrocketing cost of healthcare.” Invitae offers a transparent pricing structure independent of the number of genes required to provide an accurate diagnosis for any specific clinical indication. For payers and institutions who are in contract with Invitae, the price per indication can be as low as $950, depending on the payer’s requirements. For third-party payers with whom Invitae is out-of-network and for non-contracted institutions, the price per indication is $1,500. In addition, for patients without third-party insurance coverage or who do not meet insurance criteria for coverage, Invitae offers its full test menu for $475 per indication for patients whose clinician has ordered the testing online and who register online and pay in advance for the testing. The company is on target to reach its near-term goal of offering a test menu that includes more than 1,000 genes for under $1,000 per indication in the middle of 2016. Invitae will host a live conference call and webcast today at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss the expanded testing menu. The dial-in numbers for the conference call are (877) 201-0168 for domestic callers and (647) 788-4901 for international callers, and the reservation number for both is 55474881. The live, listen-only webcast of the conference call may be accessed by visiting the investors section of the company's website at ir.invitae.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company's website. Invitae Corporation's (NYSE: NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae’s goal is to aggregate most of the world’s genetic tests into a single service with higher quality, faster turnaround time, and lower price than many single-gene and panel tests today. The company currently provides a single diagnostic service comprising hundreds of genes for a variety of genetic disorders associated with oncology, cardiology, neurology, pediatrics and other rare disease areas. For more information, visit our website at www.invitae.com and follow us on Twitter: @invitae and @invitaeIR. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company’s belief that it offers comprehensive and affordable cancer, cardiology, neuromuscular and pediatric and rare disorder genetic tests; the benefits of genetic testing; the company’s expectations regarding the release of additional tests and the timing thereof; that the company’s current pricing and billing policies lower the cost of genetic testing and deliver savings to the healthcare system; that the company can realize its goals, including making genetic testing more affordable and accessible to billions of people; as well as the benefits of the company’s business model; and the ability of comprehensive genetic information to significantly improve care and outcomes for people around the world. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the ability of clinical trial results to affect treatment decisions; the company’s history of losses; the company’s need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the company’s ability to generate substantial demand for its tests; the company’s ability to develop and commercialize new tests and expand into new markets; the risk that the company may not obtain or maintain sufficient levels of reimbursement for its tests; risks associated with the company’s ability to use rapidly changing genetic data to interpret test results accurately and consistently; the company’s ability to compete; laws and regulations applicable to the company’s business, including potential regulation by the Food and Drug Administration; and the other risks set forth in the company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2015. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements.


News Article | August 13, 2015
Site: www.xconomy.com

Before the arrival of the summer doldrums, Global Blood Therapeutics managed to go public, although “managed” probably isn’t the right word for a debut that beat pre-IPO targets and then doubled its price the first day on the Nasdaq. It’s a big vote of confidence in the South San Francisco, CA-based company, whose lead drug is a once-a-day pill, to be taken for life, to treat sickle cell disease. If approved, it would be a welcome option for the roughly 100,000 Americans, and millions more worldwide, who have very few options other than palliative care. But it’s also a risky bet, as the disease is a target for more radical gene-therapy treatments that in a few years could displace a chronic pill. There might not be more biotech IPOs this month, but unless China’s economic malaise spreads quickly, or investors decide while at their beach houses the next couple weeks that biotech is, like, so 2014, we’re likely to see more activity after Labor Day. There ain’t no cure for the summer roundup blues, but let’s get to the rest of the week’s news. —Genetic test maker Invitae (NASDAQ: NVTA) of San Francisco and four academic collaborators published a study in JAMA Oncology that suggests testing for multiple genes implicated in breast and ovarian cancer—other than the well-known BRCA1 and BRCA2 genes—could help guide treatment decisions. Invitae presented the results as evidence that its tests are candidates for insurance reimbursement. Convincing payers that a cancer diagnostic product can change a doctor’s care decisions is a key part of the business, as I wrote about in last week’s In Translation column. —Another Bay Area test maker, GeneWEAVE Biosciences of Los Gatos, CA, exited the business via a $190 million buyout by Roche. The deal could include $235 million more in future payments if the GeneWEAVE technology to detect drug-resistant bacteria pans out. —In Washington state, the recently defunded Life Sciences Discovery Fund said it would put the $2 million left in its coffers toward grants for entrepreneurs trying to bring their ideas and products to market. —Staying Northwest, our Seattle-based biotech columnist Stewart Lyman paused to reflect upon the career of Frances Kelsey, who passed away after passing the century mark. She was the FDA regulator who saw the birth-defect problems with thalidomide in Europe and raised a red flag about the drug’s potential approval in the U.S. —There was a West Coast angle to one of the biggest private biotech fundings of the year; Bill Gates and his advisor Boris Nikolic were part of the syndicate behind gene editing startup Editas Medicine’s $120 million Series B round. —Roche’s Genentech division, based in South San Francisco, said yesterday that its drug venetoclax, to treat chronic lymphocytic leukemia with a 17p genetic deletion—found in roughly a third to half of all CLL patients—showed positive results in a pivotal Phase 2 trial. The drug is partnered with AbbVie. —Adynxx of San Francisco reported positive Phase 2 data Tuesday for its pain drug AYX1, which was tested in patients following knee replacement surgery. Photo of California’s Bixby Bridge courtesy of flickr user Giuseppe Milo via a Creative Commons license. Mille grazie, Giuseppe!


News Article | August 6, 2015
Site: www.businesswire.com

SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE:NVTA) today announced that members of the company’s management team will present at the Canaccord Genuity 35th Annual Growth Conference on Thursday, August 13, 2015 at approximately 3:30 p.m. Eastern / 12:30 p.m. Pacific in Boston, Massachusetts. The live, listen-only webcast of the presentation may be accessed by visiting the Investors section of the company’s website at ir.invitae.com. A replay of the webcasts will be available shortly after the conclusion of the presentation and will be archived on the company’s website. Invitae’s (NYSE:NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae’s goal is to aggregate most of the world’s genetic tests into a single service with higher quality, faster turnaround time and lower price than many single-gene tests today. The company currently provides a single diagnostic service comprising more than 200 genes for a variety of genetic disorders associated with oncology, cardiology, neurology, pediatrics, hematology, among other disease areas. For more information, visit our website at ir.invitae.com and follow us on @twitter: @invitae and @invitaeIR.


News Article | May 12, 2015
Site: www.businesswire.com

SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE: NVTA) today reported financial and operating results for the first quarter ended March 31, 2015. Highlights for the quarter include: In addition, Invitae is introducing new pricing programs for its tests for three customer segments: “All of this progress has enabled us to implement our new pricing programs, which ultimately allow us to provide more customers with more affordable genetic tests and services,” said Randy Scott, chairman and CEO of Invitae. “With the infrastructure we have built, we believe we are well positioned to be one of the leading players in multiple markets, at multiple price points, serving a multi-billion dollar industry.” The company reported total revenue of $1.2 million in the first quarter of 2015, compared to $118,000 in the first quarter of 2014. Total operating expenses for the first quarter of 2015 were $19.8 million, compared with $9.1 million for the first quarter of 2014. Net loss was $18.6 million in the first quarter of 2015, or a $1.09 loss per share. Indicators of our success in 2015 The four guiding indicators of success in 2015 include: 1. Reducing COGS. Invitae plans to reduce the average cost of billable reports in 2015 versus 2014. 2. Increasing content. As the company reduces the cost of its services, it plans to grow its test menu, making more content available for the same or lower prices. Invitae plans to increase its content to more than 500 genes by the end of 2015. 3. Increasing volume. The company expects that the increase in content will translate into growth in test volumes in the second half of the year as it makes more comprehensive information available to patients in existing markets and addresses new areas of medical need for genetic information. The company is confirming its guidance for 2015 of delivering 14,000-17,000 billable tests to its customers. 4. Improving reimbursement and cash collections. As volume grows, Invitae plans to streamline its billing and reimbursement functions and grow its managed care sales force. These efforts, coupled with the increased claims volumes at individual payors, should translate into more payor contracts and increased collections. Invitae will host a live conference call and webcast today at 4:45 p.m. Eastern/1:45 p.m. Pacific to discuss financial results and highlights. The dial-in numbers for the conference call are (877) 201-0168 for domestic callers and (647) 788-4901 for international callers, and the reservation number for both is 26346322. The live, listen-only webcast of the conference call may be accessed by visiting the investors section of the company's website at ir.invitae.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company's website. Invitae’s (NYSE: NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Currently focused on hereditary cancers, Invitae’s goal is to aggregate most of the world’s genetic tests into a single service with higher quality, faster turnaround time and lower price than many single-gene tests today. The company currently provides a single diagnostic service comprising more than 200 genes for a variety of genetic disorders associated primarily with cancer, but also covering cardiology, hematology, neurology and pediatrics. For more information, visit our website at ir.invitae.com and follow us on @twitter: @invitaeIR. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company’s belief that it can accelerate the adoption of comprehensive genetic information into mainstream medical care and realize its mission; the company’s expectations regarding the number of billable tests in 2015; the timing of any new testing service releases and the attributes of any such services; the company’s expectations regarding its average cost per billable test; the company’s beliefs regarding the benefits of its new pricing program; the attributes and benefits of the company’s genome management and genome network programs; and the indicators of the company’s success and its expected actions with respect to those indicators. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the company’s history of losses; the company’s need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the company’s ability to develop and commercialize new tests and expand into new markets; the risk that the company may not obtain or maintain sufficient levels of reimbursement for its tests; risks associated with the company’s ability to use rapidly changing genetic data to interpret test results accurately and consistently; the company’s ability to compete; laws and regulations applicable to the company’s business, including potential regulation by the Food and Drug Administration; and the other risks set forth in the company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Annual Report on Form 10-K for the year ended December 31, 2014. These forward-looking statements speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update these forward-looking statements. NOTE: Invitae and the Invitae logo are trademarks of Invitae Corporation. All other trademarks and service marks are the property of their respective owners. The condensed, consolidated balance sheet at December 31, 2014 has been derived from the audited consolidated financial statements at that date included in the company’s annual report on Form 10-K for the year ended December 31, 2014.

Discover hidden collaborations